HFpEF – Page 2 – Medxy AI

Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial

By MedXY 12/26/2025

This clinical review synthesizes data from the FINEARTS-HF trial, highlighting finerenone's efficacy in reducing heart failure events and cardiovascular mortality across diverse patient profiles, including those with frailty, obesity, and chronic obstructive pulmonary disease.

Cardiology news

Sudden Death Drives Excess Mortality in HFmrEF/HFpEF with EF <50% — Insights from FINEARTS‑HF

By MedXY 12/04/2025

In the FINEARTS‑HF trial, cardiovascular deaths comprised half of fatalities in HF with EF ≥40%, with sudden death accounting for the largest share — especially when EF was <50%. Finerenone did not clearly reduce cause‑specific mortality.

Cardiology Clinical Updates news Specialties

Decline in LVEF Predicts Ventricular Tachyarrhythmias and Mortality in HFpEF: Insights from the CHART-2 Study

By MedXY 09/02/2025

A mild-to-significant decline in left ventricular ejection fraction (LVEF) in heart failure with preserved ejection fraction (HFpEF) signals higher risks of lethal arrhythmias, sudden cardiac death, and mortality, underscoring the need for ongoing LVEF monitoring.

Cardiology Clinical Updates news Specialties

Personalized Accelerated Physiologic Pacing Shows Promise in HFpEF: Insights from the myPACE Trial Extension

By MedXY 08/31/2025

Personalized increased pacing rates in patients with HFpEF and physiologic pacemakers may reduce adverse events and improve event-free survival, per a 4-year observational extension of the myPACE randomized trial.

Cardiology Clinical Updates news Respiratory Specialties

Unraveling Heart-Lung Interactions in HFpEF: The Impact of Dynamic Hyperinflation on Exercise Pulmonary Capillary Wedge Pressure

By MedXY 08/24/2025

Exercise-induced dynamic hyperinflation in HFpEF patients is linked to elevated pulmonary capillary wedge pressure, suggesting altered lung mechanics contribute significantly to exercise intolerance beyond ventricular stiffness alone.

Cardiology Diabetes & Endocrinology Specialties

Untangling Adiposity and Insulin Resistance in HFpEF: Clarifying Their Distinct Impact on Cardiac Function

By MedXY 08/22/2025

This study reveals that excess adiposity, rather than insulin resistance or diabetes, predominantly drives left heart abnormalities and elevated pulmonary pressures in HFpEF, highlighting the need for targeted cardiometabolic therapies beyond glucose control.

Cardiology Diabetes & Endocrinology news Specialties

Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial

By MedXY 08/17/2025

Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.

Cardiology Clinical Updates news Specialties

Empagliflozin’s Impact on Peripheral Microvascular Function in HFpEF: A Novel Vascular Insight

By MedXY 08/13/2025

Empagliflozin alters peripheral microvascular responses in HFpEF patients, enhancing insulin-mediated vasodilation but reducing acetylcholine responsiveness, suggesting a targeted vascular mechanism distinct from general endothelial or smooth muscle effects.

Cardiology Nephrology Specialties

Examining the Link Between Obesity and Kidney Outcomes in Heart Failure with Preserved Ejection Fraction

By MedXY 08/11/2025

A pooled analysis of four heart failure trials explores the relationship between obesity and kidney outcomes, revealing waist circumference and waist-to-height ratio as key risk factors, while body mass index showed no significant association.